[go: up one dir, main page]

FR3120794B1 - Composition pour injection comprenant un conjugué peptidique - Google Patents

Composition pour injection comprenant un conjugué peptidique Download PDF

Info

Publication number
FR3120794B1
FR3120794B1 FR2102600A FR2102600A FR3120794B1 FR 3120794 B1 FR3120794 B1 FR 3120794B1 FR 2102600 A FR2102600 A FR 2102600A FR 2102600 A FR2102600 A FR 2102600A FR 3120794 B1 FR3120794 B1 FR 3120794B1
Authority
FR
France
Prior art keywords
composition
peptide conjugate
injection
unsubstituted
branched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2102600A
Other languages
English (en)
Other versions
FR3120794A1 (fr
Inventor
Nicolas Riviere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Beauty Care Solutions France SAS
Original Assignee
Rpm Dermatologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rpm Dermatologie filed Critical Rpm Dermatologie
Priority to FR2102600A priority Critical patent/FR3120794B1/fr
Priority to PCT/FR2022/050481 priority patent/WO2022195228A1/fr
Publication of FR3120794A1 publication Critical patent/FR3120794A1/fr
Application granted granted Critical
Publication of FR3120794B1 publication Critical patent/FR3120794B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24—Phosphorous; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition comprenant :a. au moins un conjugué peptidique de formule (I) suivante :R1-X1-X2-X3-X4-A1-R2 (I)dans laquelle :R1, étant du côté N-terminal, est un atome d’hydrogène, ou un groupement alkyle en C1-C50 linéaire ou ramifié, substitué ou non substitué,X1 est un condensat de (L)-sérine,X2 est un condensat de (L) et/ou (D) acide aspartique,X3 est un condensat de (L) et/ou (D) lysine, ,X4 est un condensat de (L) et/ou (D) proline,X4, ou X3 et X4, étant optionnellement absents,les liaisons reliant X1 à X2, X2 à X3 le cas échéant, et X3 à X4 le cas échéant, pouvant être des liaisons peptidiques ou pseudopeptidiques,A1 est une liaison covalente, un groupement NH ou un atome d’oxygène,R2, étant du côté C-terminal, est un atome d’hydrogène, ou un groupement alkyle en C1-C50 linéaire ou ramifié, substitué ou non substitué,R1 et R2 ne pouvant être conjointement des atomes d’hydrogène,ou l’un de ses sels physiologiquement acceptables, etb. au moins un vecteur choisi parmi les solutions aqueuses ou les biomatériaux biocompatibles de comblement.
FR2102600A 2021-03-16 2021-03-16 Composition pour injection comprenant un conjugué peptidique Active FR3120794B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR2102600A FR3120794B1 (fr) 2021-03-16 2021-03-16 Composition pour injection comprenant un conjugué peptidique
PCT/FR2022/050481 WO2022195228A1 (fr) 2021-03-16 2022-03-17 Composition pour injection comprenant un conjugué peptidique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2102600 2021-03-16
FR2102600A FR3120794B1 (fr) 2021-03-16 2021-03-16 Composition pour injection comprenant un conjugué peptidique

Publications (2)

Publication Number Publication Date
FR3120794A1 FR3120794A1 (fr) 2022-09-23
FR3120794B1 true FR3120794B1 (fr) 2023-11-24

Family

ID=76159521

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2102600A Active FR3120794B1 (fr) 2021-03-16 2021-03-16 Composition pour injection comprenant un conjugué peptidique

Country Status (2)

Country Link
FR (1) FR3120794B1 (fr)
WO (1) WO2022195228A1 (fr)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601678B1 (fr) 1986-07-18 1989-11-24 Inst Nat Sante Rech Med Peptides comprenant la sequence seryl-aspartyl-lysyl-prolyle, procede pour l'extraction du tetrapeptide correspondant, et applications, notamment a la protection de la moelle osseuse au cours de traitements anticancereux par la chimiotherapie
WO1997028183A1 (fr) 1996-02-01 1997-08-07 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Peptides inhibiteurs de la proliferation de cellules hematopoietiques
FR2872040B1 (fr) 2004-06-23 2006-09-22 Centre Nat Rech Scient Cnrse Utilisation cosmetique d'au moins un tetrapeptide naturel ac-n-ser-asp-lys-pro- ou un de ses analogues en tant qu'agent antivieillissement et restructurant de la peau
FR2882256B1 (fr) * 2005-02-18 2007-05-25 Centre Nat Rech Scient Utilisation cosmetique d'au moins un tetrapeptide naturel ac-n-ser-asp-lys-pro- ou un de ses analogues en tant qu'agent pour ralentir la chute des cheveux et/ou stimuler leur croissance
KR101110317B1 (ko) * 2009-06-30 2012-02-15 고려대학교 산학협력단 조직재생을 위한 티모신 베타-4 유래 Ａｃ-ＳＤＫＰ 펩타이드의 스마트 방출지지체
FR3047990B1 (fr) 2016-02-18 2020-12-25 Rpm Dermatologie Composition cosmetique cutanee comprenant un peptide sdkp ou un analogue de celui-ci
KR20180002228A (ko) * 2016-06-29 2018-01-08 세종대학교산학협력단 티모신-유래 Ac-SDKP를 유효성분으로 포함하는 방사선 치료 효능증진제
EP3965791A4 (fr) * 2019-05-08 2023-07-05 Alastin Skincare, Inc. Compositions et procédés pour traiter les ecchymoses et rajeunir la peau
CN111658573A (zh) * 2020-06-17 2020-09-15 广州艾尔亿医药有限公司 一种用于再生医学美容的类人血清蛋白制剂
FR3112687A1 (fr) * 2020-07-23 2022-01-28 Rpm Dermatologie Kit de soin personnalisé et personnalisable pour la peau

Also Published As

Publication number Publication date
FR3120794A1 (fr) 2022-09-23
WO2022195228A1 (fr) 2022-09-22

Similar Documents

Publication Publication Date Title
US20090099100A1 (en) Compositions and methods for treating amyloidosis
DE69912279D1 (de) 5-ht1f agonisten
JP6934011B2 (ja) Ｔｈｒｏｍｂｏｓｐｏｎｄｉｎ １結合ペプチド
MA59661B1 (fr) Conjugués de médicament anticorps comprenant des dérivés d'ectéinascidine
KR960034164A (ko) 스틸벤 유도체 및 이를 함유하는 약제학적 조성물
BR0002763A (pt) Composição cosmética para emagrecimento
DE69429984D1 (de) In position 3 durch eine stickstoffgruppe substituierte 1,3-dihydroindol-2-on derivate als vasopressin und/oder ocytocin agonisten und/oder antagonisten
Salarian et al. Precision detection of liver metastasis by collagen-targeted protein MRI contrast agent
GB2472138A (en) Cyclosporin-mitochondrial targeting group conjugates useful in the treatment of ischaemia/reperfusion injury and neurodegenerative diseases
TR199802102T2 (xx) Antifungal madde ve asetat tampon maddesi i�eren bile�imler.
FR3120794B1 (fr) Composition pour injection comprenant un conjugué peptidique
CA3004641A1 (fr) Peptides cycliques ciblant l'integrine alpha-4-beta-7
EP2044125A1 (fr) Compositions et procédés permettant d'introduire des anticorps anti-ras activée dans des cellules
KR930701481A (ko) 리포폴리사카라이드에 대해 친화성을 갖는 신규 폴리펩티드 및 그의 용도
JP2009518414A (ja) 高血糖における急性の増加および／または遊離脂肪酸流の急性の増加の病理効果を処置していくかもしくは防いでいく方法
FR2870242A1 (fr) Peptides ou conjugues peptidiques derives de la msh et leur utilisation dans le traitement cosmetique de la canitie.
BR0309283A (pt) Preparação lìquida compreendendo derivado de camptotecina e composição farmacêutica produzìvel por liofilização da preparação
SIEGERS Antidotal effects of dimethyl sulphoxide against paracetamol‐, bromobenzene‐, and thioacetamide‐induced hepatotoxicity
ES2101037T3 (es) Hexapeptido.
KR950011429A (ko) 에폭시숙신산 유도체
Miyauchi et al. Structure-activity relationships of sulfur-containing triazole antifungals
EA200100918A1 (ru) Агонисты 5-ht1f рецептора
JP2008501633A (ja) 癌の診断及び治療のためのＣａｖ３アイソフォーム及びそのδ２５スプライスバリアントの阻害
Gardiner et al. Effects of the non‐peptide, non‐selective endothelin antagonist, bosentan, on regional haemodynamic responses to NG‐monomethyl‐L‐arginine in conscious rats
Jackson Regional differences in mechanism of action of oxygen on hamster arterioles

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20220923

PLFP Fee payment

Year of fee payment: 3

TP Transmission of property

Owner name: BASF BEAUTY CARE SOLUTIONS FRANCE SAS, FR

Effective date: 20231017

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5